Insider Trading activities of Myriad Genetics Inc insiders. , Part 3

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Myriad Genetics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Myriad Genetics Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Myriad Genetics Inc since 2005. The reporting company's ticker symbol is MYGN. The reporting company's CIK number is 899923.
The total value of stock buying since 2005 is $388,130.
The total value of stock sales since 2005 is $224,372,609.
The total value of stock option exercises since 2005 is $82,982,293.


 1   2   3   4 

Table 2. Detailed insider stock purchases, sales, and option exercises of Myriad Genetics Inc insiders (MYGN) , Part 3
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2010-07-12 Capone Mark Christopher (President, MGL) Option Ex 5,000 8.63 43,150
2010-05-10 Capone Mark Christopher (President, MGL) Option Ex 2,814 9.04 25,438
2010-05-07 Evans James S (Chief Financial Officer) Option Ex 8,750 4.44 38,850
2010-05-07 Meldrum Peter D (President & C.E.O.) Option Ex 8,196 8.63 70,731
2010-03-12 Evans James S (Chief Financial Officer) Sale 6,720 24.15 162,288
2010-03-12 Evans James S (Chief Financial Officer) Option Ex 6,720 8.86 59,539
2010-03-11 Evans James S (Chief Financial Officer) Sale 1,680 23.15 38,892
2010-03-11 Evans James S (Chief Financial Officer) Option Ex 1,680 8.86 14,884
2010-03-08 Meldrum Peter D (President & C.E.O.) Sale 30,754 22.30 685,844
2010-03-08 Meldrum Peter D (President & C.E.O.) Option Ex 30,754 8.86 272,480
2010-03-05 Meldrum Peter D (President & C.E.O.) Sale 25,037 22.95 574,674
2010-03-05 Meldrum Peter D (President & C.E.O.) Option Ex 25,037 8.86 221,827
2010-03-04 Meldrum Peter D (President & C.E.O.) Sale 21,285 23.00 489,555
2010-03-04 Meldrum Peter D (President & C.E.O.) Option Ex 21,285 8.86 188,585
2010-02-18 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 7,000 7.95 55,650
2010-01-12 Marsh Richard M (V.P., General Counsel) Option Ex 9,726 7.27 70,708
2010-01-07 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 14,904 7.27 108,352
2010-01-07 Wilson Linda S (Director) Sale 30,500 26.90 820,572
2010-01-07 Wilson Linda S (Director) Option Ex 28,000 10.45 292,600
2009-12-23 Lanchbury Jerry S (Executive V.P. - Research) Sale 26,428 26.01 687,418
2009-12-11 Meldrum Peter D (President & C.E.O.) Option Ex 9,726 7.27 70,708
2009-11-05 Skolnick Mark H (Chief Scientific Officer) Sale 81,000 24.72 2,002,482
2009-11-05 Skolnick Mark H (Chief Scientific Officer) Option Ex 25,000 22.49 562,250
2009-11-04 Skolnick Mark H (Chief Scientific Officer) Sale 111,000 25.97 2,882,226
2009-11-04 Skolnick Mark H (Chief Scientific Officer) Option Ex 40,000 16.80 672,000
2009-09-10 Harrison Robert Gardner (Chief Information Officer) Sale 13,196 31.11 410,527
2009-09-10 Harrison Robert Gardner (Chief Information Officer) Option Ex 13,196 10.66 140,669
2009-08-28 Critchfield Gregory C (President Myriad Genetic Labs) Sale 46,682 30.75 1,435,378
2009-08-28 Critchfield Gregory C (President Myriad Genetic Labs) Option Ex 46,682 8.86 413,602
2009-07-13 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 15,000 7.27 109,050
2009-06-08 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 37,158 11.41 423,824
2009-05-27 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 40,000 34.01 1,360,560
2009-05-27 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 40,000 2.39 95,600
2009-05-13 Henderson John T (Director) Buy 300 32.73 9,819
2009-05-11 Skolnick Mark H (Chief Scientific Officer) Sale 6,992 32.50 227,240
2009-05-11 Skolnick Mark H (Chief Scientific Officer) Option Ex 6,992 2.39 16,710
2009-05-08 Laslie W Wayne (Chief Operating Officer, MPI) Option Ex 29,178 10.28 299,949
2009-05-08 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 5,000 10.28 51,400
2009-05-08 Critchfield Gregory C (President Myriad Genetic Labs) Option Ex 2,636 12.53 33,031
2009-05-08 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 17,742 5.82 103,258
2009-05-08 Skolnick Mark H (Chief Scientific Officer) Sale 4,601 32.59 149,946
2009-05-08 Skolnick Mark H (Chief Scientific Officer) Option Ex 4,601 2.39 10,996
2009-05-07 Belle Gerald P. (Director) Buy 1,000 32.50 32,500
2009-05-07 Skolnick Mark H (Chief Scientific Officer) Sale 10,399 32.16 334,463
2009-05-07 Skolnick Mark H (Chief Scientific Officer) Option Ex 10,399 2.39 24,853
2009-04-06 Capone Mark Christopher (Chief Operating Officer, MGL) Sale 36,000 43.09 1,551,060
2009-04-06 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 36,000 18.00 647,892
2009-03-27 Laslie W Wayne (Chief Operating Officer, MPI) Sale 24,000 44.96 1,079,040
2009-03-27 Laslie W Wayne (Chief Operating Officer, MPI) Option Ex 24,000 9.75 234,000
2009-03-26 Lanchbury Jerry S (Executive V.P. - Research) Sale 20,000 46.74 934,800
2009-03-26 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 20,000 8.48 169,700
2009-03-04 Skolnick Mark H (Chief Scientific Officer) Sale 2,000 79.00 158,000
2009-03-04 Skolnick Mark H (Chief Scientific Officer) Option Ex 2,000 4.78 9,562
2009-03-02 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 2,500 20.56 51,400
2009-02-27 Skolnick Mark H (Chief Scientific Officer) Sale 9,000 80.36 723,240
2009-02-27 Skolnick Mark H (Chief Scientific Officer) Option Ex 9,000 4.78 43,029
2009-02-23 Evans James S (Chief Financial Officer) Option Ex 7,920 5.56 44,051
2009-02-23 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 7,227 15.28 110,428
2009-02-23 Meldrum Peter D (President & C.E.O.) Option Ex 4,863 20.56 99,983
2009-02-09 Capone Mark Christopher (Chief Operating Officer, MGL) Sale 21,893 85.40 1,869,618
2009-02-09 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 15,812 30.00 474,360
2009-02-06 Lanchbury Jerry S (Executive V.P. - Research) Sale 10,000 84.31 843,080
2009-02-06 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 10,000 21.34 213,400
2009-02-05 Langer Dennis (Director) Sale 15,000 82.72 1,240,725
2009-02-05 Langer Dennis (Director) Option Ex 15,000 25.73 386,025
2009-02-05 Henderson John T (Director) Sale 10,000 82.46 824,580
2009-02-05 Henderson John T (Director) Option Ex 10,000 17.23 172,300
2009-02-05 Meldrum Peter D (President & C.E.O.) Sale 15,000 83.14 1,247,130
2009-02-05 Meldrum Peter D (President & C.E.O.) Option Ex 15,000 25.06 375,930
2009-02-04 Marsh Richard M (V.P., General Counsel) Sale 237 85.00 20,145
2009-02-04 Marsh Richard M (V.P., General Counsel) Option Ex 237 17.86 4,232
2009-02-03 Harrison Robert Gardner (Chief Information Officer) Sale 4,000 83.33 333,332
2009-02-03 Harrison Robert Gardner (Chief Information Officer) Option Ex 4,000 14.01 56,040
2009-02-03 Evans James S (Chief Financial Officer) Sale 10,964 79.68 873,611
2009-02-03 Evans James S (Chief Financial Officer) Option Ex 10,964 16.97 186,059
2009-02-03 Marsh Richard M (V.P., General Counsel) Sale 10,763 85.00 914,855
2009-02-03 Marsh Richard M (V.P., General Counsel) Option Ex 10,763 17.86 192,227
2009-02-03 Meldrum Peter D (President & C.E.O.) Sale 10,000 82.06 820,610
2009-02-02 Marsh Richard M (V.P., General Counsel) Option Ex 4,863 20.56 99,983
2009-01-30 Marsh Richard M (V.P., General Counsel) Sale 9,804 75.03 735,603
2009-01-30 Marsh Richard M (V.P., General Counsel) Option Ex 9,804 17.86 175,099
2009-01-29 Marsh Richard M (V.P., General Counsel) Sale 1,800 75.06 135,115
2009-01-29 Marsh Richard M (V.P., General Counsel) Option Ex 1,800 17.86 32,148
2009-01-29 Critchfield Gregory C (President Myriad Genetic Labs) Option Ex 14,000 4.78 66,934
2009-01-28 Critchfield Gregory C (President Myriad Genetic Labs) Sale 20,000 74.50 1,490,000
2009-01-28 Critchfield Gregory C (President Myriad Genetic Labs) Option Ex 20,000 16.64 332,800
2009-01-06 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 5,000 20.56 102,800
2008-12-18 Lanchbury Jerry S (Executive V.P. - Research) Sale 10,000 67.00 670,000
2008-12-18 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 10,000 18.77 187,650
2008-12-11 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 20,000 60.60 1,212,060
2008-12-11 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 20,000 4.78 95,620
2008-12-09 Wilson Linda S (Director) Sale 16,000 63.91 1,022,608
2008-12-09 Wilson Linda S (Director) Option Ex 16,000 34.57 553,120
2008-11-21 Laslie W Wayne (Chief Operating Officer, MPI) Option Ex 5,128 19.50 99,996
2008-11-10 Skolnick Mark H (Chief Scientific Officer) Sale 10,000 71.15 711,500
2008-11-10 Skolnick Mark H (Chief Scientific Officer) Option Ex 10,000 4.78 47,810
2008-11-04 Laslie W Wayne (Chief Operating Officer, MPI) Sale 12,000 70.00 840,000
2008-11-04 Laslie W Wayne (Chief Operating Officer, MPI) Option Ex 12,000 19.50 234,000
2008-11-04 Meldrum Peter D (President & C.E.O.) Sale 10,000 70.26 702,630
2008-09-29 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 21,068 5.12 107,973
2008-09-25 Evans James S (Chief Financial Officer) Sale 6,669 69.00 460,161
2008-09-25 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 15,000 68.54 1,028,130
2008-09-23 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 10,000 5.12 51,250
2008-09-19 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 992 66.00 65,472
2008-09-19 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 992 5.12 5,084
2008-09-19 Wilson Linda S (Director) Sale 12,500 65.81 822,575
2008-09-19 Wilson Linda S (Director) Option Ex 12,500 28.02 350,275
2008-09-18 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 10,000 5.12 51,250
2008-09-17 Critchfield Gregory C (President Myriad Genetic Labs) Sale 32,380 66.08 2,139,638
2008-09-17 Critchfield Gregory C (President Myriad Genetic Labs) Option Ex 32,380 12.54 406,045
2008-09-17 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 500 66.49 33,245
2008-09-17 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 500 5.12 2,562
2008-09-16 Skolnick Mark H (Chief Scientific Officer) Sale 19,500 66.00 1,287,000
2008-09-09 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 3,000 15.28 45,840
2008-09-08 Hockett William A Iii (V. P. of Corp Communications) Sale 28,447 64.03 1,821,603
2008-09-08 Hockett William A Iii (V. P. of Corp Communications) Option Ex 28,447 28.63 814,380
2008-09-05 Langer Dennis (Director) Sale 4,280 63.50 271,780
2008-09-05 Langer Dennis (Director) Option Ex 4,280 21.49 91,977
2008-09-05 Gilbert Walter Phd (Director) Sale 10,000 63.31 633,100
2008-09-05 Gilbert Walter Phd (Director) Option Ex 10,000 25.73 257,350
2008-09-04 Langer Dennis (Director) Sale 5,720 65.73 375,969
2008-09-04 Langer Dennis (Director) Option Ex 5,720 21.49 122,922
2008-09-04 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 6,714 17.68 118,737
2008-09-03 Lanchbury Jerry S (Executive V.P. - Research) Sale 20,000 67.07 1,341,480
2008-09-03 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 20,000 16.64 332,800
2008-09-03 Skolnick Mark H (Chief Scientific Officer) Sale 500 68.51 34,257
2008-09-02 Meldrum Peter D (President & C.E.O.) Option Ex 9,727 28.16 273,912
2008-08-29 Capone Mark Christopher (Chief Operating Officer, MGL) Sale 18,000 67.93 1,222,812
2008-08-29 Capone Mark Christopher (Chief Operating Officer, MGL) Option Ex 18,000 18.90 340,164
2008-08-29 Marsh Richard M (V.P., General Counsel) Sale 11,198 68.26 764,353
2008-08-29 Marsh Richard M (V.P., General Counsel) Option Ex 11,198 17.86 199,996
2008-08-29 Meldrum Peter D (President & C.E.O.) Sale 15,998 68.07 1,088,919
2008-08-29 Meldrum Peter D (President & C.E.O.) Option Ex 15,998 4.78 76,486
2008-08-27 Harrison Robert Gardner (Chief Information Officer) Sale 4,085 65.90 269,201
2008-08-27 Harrison Robert Gardner (Chief Information Officer) Option Ex 4,085 11.09 45,302
2008-08-25 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Sale 27,464 65.03 1,785,928
2008-08-25 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 27,464 5.12 140,753
2008-05-19 Wilson Linda S (Director) Option Ex 50 29.98 1,499
2008-04-14 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 3,500 14.81 51,835
2008-03-20 Skolnick Mark H (Chief Scientific Officer) Sale 20,000 35.12 701,415
2008-03-20 Skolnick Mark H (Chief Scientific Officer) Option Ex 20,000 9.31 186,239
2008-03-10 Lanchbury Jerry S (Executive V.P. - Research) Option Ex 3,000 14.81 44,430
2008-03-10 Hobden Adrian N (Pres. Myriad Pharmaceuticals) Option Ex 10,000 5.12 51,250
2008-03-10 Meldrum Peter D (President & C.E.O.) Option Ex 2,462 25.06 61,702
2008-03-04 Hockett William A Iii (V. P. of Corp Communications) Option Ex 8,693 11.64 101,186
2008-02-12 Marsh Richard M (V.P., General Counsel) Option Ex 6,526 20.56 134,174
2008-02-07 Skolnick Mark H (Chief Scientific Officer) Sale 25,000 39.21 977,390
2008-02-07 Skolnick Mark H (Chief Scientific Officer) Option Ex 25,000 9.31 232,799
2008-02-01 Evans James S (Chief Financial Officer) Option Ex 6,000 5.12 30,750
2008-01-30 Skolnick Mark H (Chief Scientific Officer) Option Ex 25,000 9.31 232,799
 1   2   3   4 

Insider trading activities including stock purchases, stock sales, and option exercises of MYGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Myriad Genetics Inc (symbol MYGN, CIK number 899923) see the Securities and Exchange Commission (SEC) website.